Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eirion Therapeutics

http://www.eirionthera.com/

Latest From Eirion Therapeutics

Finance Watch: Cell And Gene Therapy Firms Raised Nearly $20bn In 2020

Private Company Edition: Venture capital mega-rounds continue a brisk pace with machine learning-based drug discovery firm insitro and gene therapy developer Graphite Bio among recent $100m-plus deals. Also, Argobio raised €50m to fund five start-ups in Europe. 

Financing Innovation

Biopharma Quarterly Dealmaking Statistics, Q1 2016

Q1 biopharma financing totaled $5.7 billion, a sharp drop from Q4, but this time early-stage venture rounds were the most popular fundraising vehicle;Q1 M&A also declined, totaling $12.3 billion, mostly from Mylan's $9.9 billion buy of Meda. The top alliance was again by Sanofi, in a five-year potential $2.26 billion collaboration with DiCE Molecules to develop oral small-molecule therapies against up to 12 targets.

BioPharmaceutical Deals

Deal Watch: Big Pharmas Lead Hectic New Year Deal-Making Pace

J&J Innovation's spate of deals led a busy week of deal-making involving many big pharmas. Sanofi exited its inhaled insulin partnership with MannKind, Merck collaborated with Quartet and Complix, Roche partnered with and helped finance C4, and Pfizer signed an immuno-oncology combo trial agreement with Syndax.

BioPharmaceutical Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register